{"product_id":"procapsgroup-bcg-matrix","title":"Procaps Group Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eProcaps Group’s preliminary BCG Matrix shows a dynamic mix of offerings amid shifting pharma markets—some products appear as Stars driving growth, while others verge on Cash Cows or Question Marks requiring strategic focus. This snapshot hints at where management should prioritize R\u0026amp;D, M\u0026amp;A, or divestment to maximize ROI and operational efficiency. Dive deeper into the full BCG Matrix for quadrant-by-quadrant placement, data-backed recommendations, and a ready-to-use strategic roadmap. Purchase the complete report (Word + Excel) to act with clarity and speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNextGel iCDMO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, NextGel iCDMO is Procaps Group’s primary growth engine, using proprietary softgel tech to serve a global softgel market forecast at ~$8.9B by 2026; Procaps ranks top-five in global softgel capacity and reported NextGel revenue growth of ~28% YoY in 2024-25.\u003c\/p\u003e\n\u003cp\u003eThe unit demands continued capex and R\u0026amp;D—Procaps disclosed ~$45M capex and 6% of revenue into R\u0026amp;D in 2025—to defend share vs Catalent and Lonza and to scale advanced manufacturing for specialty softgel contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Softgel Technology (Unigel and Versagel)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps uses patented Unigel and plant-based Versagel to encapsulate multiple actives per softgel, targeting a multi-billion global nutraceutical delivery market valued at $15.3B in 2024; this tech fuels premium, vegan products that drove Procaps to ~45% market share in LATAM softgel segments in 2024.\u003c\/p\u003e\n\u003cp\u003eThese Stars require heavy cash: Procaps spent ~$18M in 2024 on clinical trials and $12M on global marketing to pursue US\/EU approval and launch, squeezing free cash flow despite high ASPs and strong regional sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and High-Potency Clinical Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps Group’s Oncology and High-Potency Clinical Solutions business is a Star: it serves a high-growth oncology niche with ~12% CAGR global oncology drugs (2024–29) and uses one of South America’s few FDA-approved high-potency plants, enabling exports to US\/EU markets.\u003c\/p\u003e\n\u003cp\u003ePost-2025 restructuring, Procaps committed $45m to scale this segment, targeting a 30% capacity increase and alignment with EU GMP by Q4 2026 to capture higher-margin contract manufacturing opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceuticals and Dietary Supplements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe global shift to preventive health made nutraceutical softgels a star, growing ~7–9% CAGR vs pharmaceuticals' ~2–3% (2020–2025); softgels now drive higher margins and faster SKU velocity.\u003c\/p\u003e\n\u003cp\u003eProcaps leads market share in 13 Americas countries via Funtrition (gummies + softgels), with 2024 nutraceutical revenue ~US$120M and double-digit segment margins.\u003c\/p\u003e\n\u003cp\u003eTo sustain \u0026gt;7% market growth, Procaps must invest in brand placement, cold-chain and contract manufacturing capacity—capex likely 5–8% of revenue annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSoftgels: 7–9% CAGR (2020–2025)\u003c\/li\u003e\n\u003cli\u003eProcaps: market leader in 13 countries\u003c\/li\u003e\n\u003cli\u003e2024 nutraceutical rev: ~US$120M\u003c\/li\u003e\n\u003cli\u003eCapex needed: 5–8% revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS Market B2B Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcaps Group targets the United States as a core B2B cluster, using its lower-cost Colombian manufacturing to supply US pharma firms; revenue from US contracts rose ~28% in 2024 to an estimated $45m, signaling rapid scale-up.\u003c\/p\u003e\n\u003cp\u003eThe US B2B expansion sits in the BCG Matrix Stars quadrant: high market growth (US pharma market ~5.6% CAGR to 2026) but currently lower share vs incumbents, so Procaps needs sustained capex and commercial investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 US B2B revenue ≈ $45m\u003c\/li\u003e\n\u003cli\u003eYoY growth ~28% (2023–24)\u003c\/li\u003e\n\u003cli\u003eUS pharma market CAGR ≈ 5.6% to 2026\u003c\/li\u003e\n\u003cli\u003eStrategy: scale manufacturing, regulatory filings, commercial partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNextGel: iCDMO \u0026amp; Oncology Lead Rapid US\/EU Growth Despite Heavy Capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNextGel iCDMO and Oncology\/High-Potency are Stars: high growth, leading tech, and rising US\/EU revenues but heavy capex\/R\u0026amp;D (Procaps disclosed $45M capex and 6% revenue R\u0026amp;D in 2025; 2024 nutraceutical rev ≈ $120M; US B2B rev ≈ $45M, +28% YoY).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 capex\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e6% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 nutraceutical rev\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 US B2B rev\u003c\/td\u003e\n\u003ctd\u003e$45M (+28% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Procaps Group’s portfolio with quadrant-specific strategic recommendations, competitive risks, and investment priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Procaps Group BCG Matrix placing each business unit in a quadrant for fast portfolio clarity and strategic action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps Colombia (B2C Pharma)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Colombia, the group's B2C pharma arm, is its most mature unit, holding roughly 35–40% share of the Colombian OTC and generics market as of year-end 2025 and delivering stable EBITDA margins near 18% that generate consistent free cash flow to fund growth projects.\u003c\/p\u003e\n\u003cp\u003eThis cash cow supports Procaps Group's pipeline investments and services the restructured debt facility signed in 2024, contributing an estimated COP 120–150 billion in annual operating cash flow in 2025.\u003c\/p\u003e\n\u003cp\u003eBrands are household names across Colombia, so marketing spend stays moderate—around 4–5% of sales versus 10–12% in newer markets—keeping net cash conversion high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded Prescription Drugs (Rx)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Rx product line, with established feminine care and pain-relief brands, generates steady cash due to high patient loyalty and physician prescribing; Procaps reported pharmaceutical revenue of $152.4M in 2024, with Rx contributing ~58% of sales.\u003c\/p\u003e\n\u003cp\u003eThese products compete in mature markets where Procaps has cut COGS by 6.5% since 2021 through scale and optimized distribution across Latin America and the US.\u003c\/p\u003e\n\u003cp\u003eHigh gross margins—around 48% on Rx in 2024—provide critical funding for the company’s turnaround and remediation plan, which targets $25M in operational savings through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-the-Counter (OTC) Medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps’ OTC portfolio, led by liquid-filled softgel analgesics, holds estimated market shares of 20–35% in key Central and South American markets and generates steady annual revenues around $120–150 million in 2024. These products face stable demand and use Procaps’ mature manufacturing and retail distribution—requiring maintenance CAPEX under 3% of sales. Cash flow from OTCs funds roughly 40% of corporate G\u0026amp;A and about $8–12 million yearly R\u0026amp;D for advanced delivery systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftgel Manufacturing for Regional Leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLong-term 5–10 year manufacturing contracts with Latin American pharma leaders give Procaps Group predictable revenue; as of FY2024 these agreements backed roughly 60% of regional softgel plant capacity and ~US$85M in annual recurring revenue.\u003c\/p\u003e\n\u003cp\u003eThis B2B model cuts customer acquisition cost, keeps factory utilization above 80% historically, and generates steady cash flow Procaps uses to fund riskier international expansion and R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5–10 year contracts\u003c\/li\u003e\n\u003cli\u003e~US$85M recurring revenue (2024)\u003c\/li\u003e\n\u003cli\u003e~60% capacity tied to partners\u003c\/li\u003e\n\u003cli\u003e\u0026gt;80% plant utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHormonal and Specialized Softgel Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs one of the few regional players with FDA-approved hormonal softgel facilities, Procaps holds a defensible position in a stable niche, supplying hospitals and B2B partners across Latin America; 2024 revenue from softgels was roughly $85–95M, driving strong free cash flow.\u003c\/p\u003e\n\u003cp\u003eHigh technical barriers—cGMP compliance, specialized encapsulation tech, and regulatory track record—protect share, enable gross margins near 40%, and sustain steady cash generation from a mature product line.\u003c\/p\u003e\n\u003cp\u003eMinimal promotion needed: clinicians and institutional buyers recognize value, so OPEX for marketing in this segment stays low, preserving operating margins and ROI.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 softgel revenue ≈ $85–95M\u003c\/li\u003e\n\u003cli\u003eGross margin ≈ 40%\u003c\/li\u003e\n\u003cli\u003eLow marketing spend; high repeat B2B contracts\u003c\/li\u003e\n\u003cli\u003eFDA-approved facility = high entry barriers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps cash cows: Colombia B2C dominance, $120–150M OTC \u0026amp; $85–95M softgels, ~18% EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps’ cash cows: Colombia B2C (35–40% OTC\/generics share, EBITDA ~18%, ~COP120–150bn OCF 2025), OTC revenues $120–150M (2024), Rx revenue 58% of $152.4M (2024), softgels $85–95M (2024) with ~40% gross margin and \u0026gt;80% plant utilization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eColombia share\u003c\/td\u003e\n\u003ctd\u003e35–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCF\u003c\/td\u003e\n\u003ctd\u003eCOP120–150bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftgels rev\u003c\/td\u003e\n\u003ctd\u003e$85–95M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eProcaps Group BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Procaps Group BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the final deliverable: a market-informed BCG Matrix crafted for strategic clarity, ready to download, edit, print, or present to stakeholders.\u003c\/p\u003e\n\u003cp\u003eOnce purchased, the same document shown here is sent to your inbox—no surprises, no revisions needed, just professional, plug-and-play analysis.\u003c\/p\u003e\n\u003cp\u003eDesigned by strategy experts, this BCG Matrix is tailored for immediate use in business planning, portfolio review, or executive presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748513395065,"sku":"procapsgroup-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/procapsgroup-bcg-matrix.png?v=1772209018","url":"https:\/\/matrixbcg.com\/products\/procapsgroup-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}